Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-09 · 1881 (4) · 189617
DOI: 10.1016/j.bbcan.2026.189617 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-09. Verfasst von Yinchun Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Genetic Heterogeneity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Province Department of Science and Technology, Sichuan Normal University, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Tumor heterogeneity is a fundamental feature of malignant tumors and a major driver of treatment resistance, ultimately contributing to treatment resistance, therapeutic failure, disease recurrence, and poor outcome. Rather than being static, heterogeneity arises early during tumorigenesis and continues to evolve during progression, metastasis, and therapeutic selection. Advances in single-cell and spatial omics, integrative multi-omics profiling, liquid biopsy, and computational modeling have markedly improved the characterization of heterogeneity across genetic, epigenetic, transcriptomic, phenotypic, and microenvironmental dimensions. However, translating heterogeneity profiling into routine clinical decision-making remains challenging due to sampling bias, technical variability, data-integration complexity, and the need for prospectively validated, actionable metrics. In this review, we summarize the biological origins and major classifications of tumor heterogeneity, discuss current approaches for its detection and longitudinal monitoring, examine its implications for established and emerging therapies, and highlight precision-oncology strategies aimed at anticipating, tracking, and ultimately exploiting heterogeneity to achieve durable cancer control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
- Division of Gastrointestinal, Bariatric and Metabolic Surgery, Department of General Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China. Electronic addr…
- Division of Gastrointestinal, Bariatric and Metabolic Surgery, Department of General Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China; Department of O…
Förderung
- Sichuan Province Department of Science and Technology
- Sichuan Normal University
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Lv, Y., He, C., Xie, Q., Long, F., & Fan, C. (2026). Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(4), 189617. https://doi.org/10.1016/j.bbcan.2026.189617
Vancouver
Lv Y, He C, Xie Q, Long F, Fan C. Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(4):189617. doi:10.1016/j.bbcan.2026.189617
BibTeX
@article{Lv2026,
author = {Lv, Yinchun and He, Chenjia and Xie, Qibing and Long, Feiwu and Fan, Chuanwen},
title = {Understanding tumor heterogeneity: Implications for precision oncology and therapeutic strategies},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {4},
pages = {189617},
doi = {10.1016/j.bbcan.2026.189617}
}
EUVIMED